Bobby Sandage

Bobby W.
Sandage currently works at Euclises Pharmaceuticals, Inc., as President & Chief Executive Officer from 2015, Immunophotonics, Inc., as Chairman from 2015, Electronic Drug Information Systems Solutions LLC, as Director, Arch Oncology, Inc., as Director, Geneoscopy, Inc., as Director, Lightchain Capital LLC, as Managing Director, NextRNA Therapeutics, Inc., as Director, AI Proteins, Inc., as Director, Endevica Bio, Inc., as Director from 2017, Paula And Rodger Riney Foundation, as Managing Director from 2020, Bioventures LLC, as Board Member from 2019, Cultivation Capital LLC, as General Partner from 2014, and Microbial Machines, Inc., as Board Member from 2022.
Dr. Sandage also formerly worked at Oncotelic Therapeutics, Inc., as Independent Director from 2016 to 2019, Genta, Inc., as Director, Gentium Srl, as Director from 2009 to 2012, Osteologix, Inc., as Director, Fortress Biotech, Inc., as President & Director from 2012 to 2013, DuPont Merck Pharmaceutical Co., as Associate Director-Project Management from 1989 to 1991, Osteologix Holdings Plc, as Director from 2005 to 2010, Dupont Critical Care, Inc., as Associate Medical Director-Medical Development from 1985 to 1989, American Critical Care Services, Inc., as Associate Medical Director from 1983 to 1986, Indevus Pharmaceuticals, Inc., as CSO, Executive VP-Research & Development from 1991 to 2009, Endo Health Solutions, Inc., as Vice President, Endo Pharmaceuticals, Inc., as Executive Vice President, Covidien Unlimited Co., as Vice President-Embedded Therapeutics from 2010 to 2011, and Merrell Dow Pharmaceuticals, Inc., as Principal.
Dr. Sandage received his undergraduate degree from The University of Arkansas and doctorate degree from Purdue University.